MetLife Investment Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

MetLife Investment Management’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-414	Closed	-$10.1K	–	2851
2022 Q2	$10.1K	Sell	414 -3,296	-89%	-$112K	﹤0.01%	2851
2022 Q1	$185K	Buy	3,710 +1,362	+58%	+$67.3K	﹤0.01%	2390
2021 Q4	$165K	Buy	2,348 +729	+45%	+$61.4K	﹤0.01%	2174
2021 Q3	$151K	Sell	1,619 -852	-34%	-$80.9K	﹤0.01%	2254
2021 Q2	$248K	Hold	2,471	–	–	﹤0.01%	2017
2021 Q1	$231K	Buy	2,471 +941	+62%	+$95.4K	﹤0.01%	1979
2020 Q4	$126K	Sell	1,530 -308	-17%	-$26.3K	﹤0.01%	2194
2020 Q3	$158K	Sell	1,838 -781	-30%	-$91K	﹤0.01%	2001
2020 Q2	$244K	Buy	+2,619	New	+$144K	﹤0.01%	1783

Other funds holding VBIV

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's VBIV Position: Q3 2022 in Review

MetLife Investment Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2022, closing a stake of 414 shares — an estimated $10.1K sold.

MetLife Investment Management first reported a position in VBIV in Q2 2020 and held it in 9 quarters. The position peaked at $248K in Q2 2021. 127 funds tracked by Wall St. Rank hold VBIV as of Q3 2022.

MetLife Investment Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2022 after selling out during the quarter.
MetLife Investment Management sold 414 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2022, an estimated $10.1K.
MetLife Investment Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2020 and held it in 9 quarters.
MetLife Investment Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $248K in Q2 2021.
127 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2022.

Based on MetLife Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.